Autoimmune Thrombocytopenia (AITP) Research Study
|
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Platelets are particles found along with red and white blood cells in the blood that play a role in the process of blood clotting. Disorders affecting the platelets can lower the amount of platelets in the blood and put patients at risk of bleeding. The condition of low platelets is referred to as thrombocytopenia. Autoimmune thrombocytopenia (AITP) is a disorder of low blood platelet counts in which platelets are destroyed by antibodies produced by the immune system. Unfortunately, many patients with AITP do not respond to standard treatments for thrombocytopenia. Cyclophosphamide is a drug that works to suppress the activity of the immune system. We will combine this drug with transfusion of cells that form red and white blood cells and platelets (called stem cells) collected from the patient prior to this treatment.The purpose of this study is to explore the safety and effectiveness of this therapy for the treatment of AITP.
To inquire about eligibility, contact us by e-mail at
BloodStudy@nhlbi.nih.gov or call our research co-ordinator at 301-594-4180.
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Support Groups |
|
| |
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute